

#### ANALYTICAL REPORT - SUMMARY

We maintain our BUY recommendation for the company's shares, lowering the target price to PLN 5.0 per share (previously PLN 5.3). The Q3 2025 results turned out to be weaker than our assumptions and, in our opinion, showed the scale of changes introduced by the management board, which are necessary to streamline the company's operations. We are lowering our short-term assumptions, but in our opinion, the company's long-term prospects are the most important factor in our valuation.

The results for Q1-Q3 2025 showed a significant year-on-year decline. The company made a number of changes, the most important of which was the switch from ampoules to vials, which made it necessary to participate in new tenders. In addition, as the CEO said in an interview with PAP Biznes, many of the contracted tenders were protested by competitors, which caused delays in deliveries. Expansion into new markets where there are shortages of Onko BCG also proved slower than previously anticipated. These processes are more difficult and take longer than the company expected.

In Q1 2026, Synthaverse plans to complete the transfer of technology to the new plant and produce the first three validation series, the stability of which will be assessed after six months. After that, it will be able to submit registration documentation, with procedures expected to take another 7-8 months. The company expects to start selling Onko BCG produced at the new manufacturing plant in Q4 2027.

In our previous recommendation, we assumed that sales from the new plant would commence in 2027, but around the middle of the year. The change in dates, which in our opinion is largely independent of the company and is due to protracted administrative processes, has caused us to lower our short- and medium-term forecasts once again.

Due to the commissioning of the new production plant, we estimate that in 2026 depreciation costs will increase to approximately PLN 4.2 million per quarter, compared to PLN 3.2 million in Q3 2025. We expect revenue growth and improved results, but in the current situation we forecast an EBIT and net loss in 2026. This is due to lower assumptions regarding the pace of foreign expansion and high fixed costs.

In the long term, we maintain our assumptions regarding the utilisation of planned capacity at Onko BCG and cooperation with the WHO in the sale of the BCG10 vaccine on the UNICEF market.

	2022	2023	2024	2025F	2026F	2027F
Revenues [PLNm]	50.4	58.6	71.8	43.0	58.7	85.0
EBIT [PLNm]	9.8	8.6	12.4	-10.9	-0.2	21.4
EBITDA [PLNm]	16.1	15.3	19.1	2.4	16.4	37.5
Net income [PLNm]	6.1	4.8	7.6	-13.2	-4.1	12.1
P/E	41.0	52.6	33.3	-	-	22.9
P/BV	2.4	2.2	2.1	2.1	2.2	2.0
EV/EBIT	24.1	36.8	26.6	-	-	15.1
EV/EBITDA	14.8	20.8	17.4	145.9	20.8	8.6
DPS	0.0	0.0	0.0	0.0	0.0	0.0
DY	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

# BUY

(PREVIOUS: BUY)

#### **TARGET PRICE 5.0 PLN**

18 DECEMBER 2025, 07:50 CET

Target price [PLN]	5.0
DCF valuation [PLN]	5.9
Peer valuation [PLN]	2.4
Price upside/downside	41.7%
Cost of capital	11.7%
Price [PLN]	3.6
Market cap [PLNm]	249.4
No. of shares [mn]	78.4*
Max. price 6M [PLN]	5.3
Min. price 6m [PLN]	3.6
Rate of return 3M	-19.0%
Rate of return 6M	-28.1%
Rate of return 9M	-23.7%
Shareholders (% of votes):	
Dariusz Kucowicz	10.5%
Wiktor Napióra	10.5%
Waldemar Sierocki	9.7%
Przemysław Sierocki	9.6%
AgioFunds TFI	5.5%
Others	54.3%

\* target number of shares (as part of the capital increase and incentive scheme, it is possible to issue 2.7 million shares)

# Anna Tobiasz, DI anna.tobiasz@bdm.pl tel. (+48) 666 073 972 Dom Maklerski BDM S.A. ul. 3-go Maja 23, 40-096 Katowice



Valuation summary		
	Share	Valuation
DCF valution	75%	5.9
Peer valuation	25%	2.4
Target price [DLN]		E 0

DCF Valution				13/0	3.5					
Peer valuation			2	25%	2.4					
Target price [PLN]				5.0	)					
Source: BDM S.A.										
DCF valuation										
	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034
Revenues [PLNm]	43.0	58.7	85.0	130.9	173.8	180.8	187.1	193.7	200.4	207.5
EBIT [PLNm]	-10.9	-0.2	21.4	50.6	76.8	80.6	83.5	86.6	89.8	93.2
Incentive programme cost	1.2	1.2	1.2	1.2	0.0	0.0	0.0	0.0	0.0	0.0
EBIT Adj. [PLNm]	-9.7	1.0	22.6	51.8	76.8	80.6	83.5	86.6	89.8	93.2
Tax rate	14.3%	19.0%	23.0%	22.0%	21.0%	21.0%	21.0%	21.0%	21.0%	21.0%
Tax on EBIT [PLNm]	-1.4	0.2	5.2	11.4	16.1	16.9	17.5	18.2	18.9	19.6
NOPLAT [PLNm]	-8.4	0.8	17.4	40.4	60.7	63.6	66.0	68.4	71.0	73.6
Amortization [PLNm]	13.3	16.6	16.1	15.6	17.1	16.4	16.1	15.9	15.7	15.6
CAPEX [PLNm]	-22.6	-10.6	-9.7	-10.3	-11.0	-12.3	-12.9	-13.4	-14.4	-15.6
Working capital movement [PLNm]	1.9	13.8	1.6	-5.7	-5.4	-0.9	-0.8	-0.8	-0.8	-0.9
FCF [PLNm]	-15.8	20.6	25.3	40.0	61.4	66.8	68.5	70.1	71.4	72.7
DFCF [PLNm]	-15.7	18.5	20.5	29.1	40.0	39.0	35.7	32.8	29.9	27.3
Total DFCF [PLNm]	257.1									
Terminal value [PLNm]	764.9			Termina	growth ra	te: 2.0%				
Discounted terminal value [PLNm]	286.6				J					
Enterprise value [PLNm]	543.7									
Net debt [PLNm]*	79.6									
Equity value [PLNm]	464.0									
Number of shares [mn]	78.4									
Value per share [PLN]	5.9									
WACC calculation										
	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034
Risk-free rate	5.3%	5.3%	5.3%	5.3%	5.3%	5.3%	5.3%	5.3%	5.3%	5.3%
Risk premium	8.0%	8.0%	8.0%	8.0%	8.0%	8.0%	8.0%	8.0%	8.0%	8.0%
Beta	0.8	8.0	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.8
Credit premium	5.0%	5.0%	5.0%	5.0%	5.0%	5.0%	5.0%	5.0%	5.0%	5.0%
Cost of equity	11.7%	11.7%	11.7%	11.7%	11.7%	11.7%	11.7%	11.7%	11.7%	11.7%
Contribution of equity	73.1%	76.3%	82.1%	86.4%	98.7%	99.8%	100.0%	100.0%	100.0%	100.0%
Cost of debt after tax	8.8%	8.3%	7.9%	8.0%	8.1%	8.1%	8.1%	8.1%	8.1%	8.1%

Source: BDM S.A.

WACC

Sensivity analysis

Contribution of debt

	,													
		Tern	ninal growth	rate			Tern	ninal growth	rate				Beta	
		1.0%	2.0%	3.0%			1.0%	2.0%	3.0%			0.7	0.8	0.9
Data	0.7	6.1	6.6	7.2	Risk	7.0%	6.1	6.6	7.2	Risk	7.0%	7.3	6.6	6.0
Beta	0.8	5.5	5.9	6.4	premium	8.0%	5.5	5.9	6.4	premium	8.0%	6.6	5.9	5.3
	0.9	5.0	5.3	5.7		9.0%	5.0	5.3	5.7		9.0%	6.0	5.3	4.8

17.9%

11.0%

13.6%

11.2%

1.3%

11.7%

0.2%

11.7%

0.0%

11.7%

0.0%

11.7%

0.0%

0.0%

11.7%

Source: BDM S.A.

# Peer valuation

		EV/EBITDA	
	2025F	2026F	2027F
MERCK & CO. INC.	9.6	10.2	8.4
GRIFOLS SA	8.4	7.6	6.5
IPSEN	6.2	5.9	5.1
H LUNDBECK A/S	6.6	5.7	5.0
RECORDATI INDUSTRIA CHIMICA	12.5	11.6	10.2
SWEDISH ORPHAN BIOVITRUM AB	13.0	10.0	8.0
UCB SA	20.8	15.9	12.2
Median	9.6	10.0	8.0
SYNTHAVERSE	145.9	20.8	8.6
Premium/discount	1419%	109%	8%
Valuation [PLN/share]	-	1.4	3.4
Year's contribution	0%	50%	50%
Average valuation [PLN/share]		2.4	
Multiple's contribution		100%	
Value per share [PLN]		2.4	
Source: BDM S.A., Bloombera			

26.9%

10.9%

23.7%

Source: BDM S.A., Bloomberg

Main risks: 1) Risk of delay in commissioning new capacity; 2) Risk of delayed registration processes; 3) Foreign exchange and interest rate risk; 4) Risk of rising energy and gas prices; 5) risk of new competitive products entering the market; 6) Product withdrawal risk; 7) Risk of side effects or interactions with new drugs



# RESEARCH DEPARTMENT:

# Maciej Bobrowski

Director

Investment Adviser tel. (032) 208 14 12

e-mail: maciej.bobrowski@bdm.pl

 $\underline{\text{Strategy, industry, media/entertainment, TMT}}$ 

#### **Krzysztof Pado**

Deputy Director Investment Adviser tel. (032) 208 14 32

e-mail: krzysztof.pado@bdm.pl

oil&gas, construction, building materials, real estate

#### Anna Tobiasz

Junior analyst Investment Adviser tel. (032) 208 14 35

e-mail: anna.tobiasz@bdm.pl

#### Piotr Barcz

Junior analyst Investment Adviser tel. (032) 208 14 39 e-mail: piotr.barcz@bdm.pl

# INSTITUTIONAL SALES DEPARTMENT:

# Leszek Mackiewicz

Director

tel. (022) 62-20-848

e-mail: leszek.mackiewicz@bdm.pl

# Maciej Fink-Finowicki

tel. (022) 62-20-855

 $e\text{-mail:}\ \underline{maciej.fink\text{-}finowicki@bdm.pl}$ 

#### Tomasz Grzeszczyk

tel. (022) 62-20-854

 $e\hbox{-mail: tomasz.grzeszczyk@bdm.pl}$ 

# Piotr Komorowski

tel. (022) 62-20-851

e-mail: piotr.komorowski@bdm.pl

#### Ratings and price targets history:

rating	price target	previous rating	previous target price	report date	report date (hour)	price	WIG
Buy	5.0	Buy	5.3	18.12.2025*	07:50 CET	3.55	114 381.38
Buy	5.3	Buy	6.6	20.10.2025*	15:55 CEST	4.22	109 276.48
Buy	6.6	Buy	6.1	20.05.2025*	18:09 CEST	5.70	102 543.24
Buy	6.1	Buy	6.1	30.01.2025*	15:25 CET	4.73	87 148.74
Buy	6.1	Accumulate	6.1	06.11.2024*	07:55 CET	4.30	80 271.30
Accumulate	6.1	Buy	6.5	12.07.2024*	15:50 CEST	5.62	88 398.89
Buy	6.5	Buy	6.7	10.05.2024*	08:30 CEST	4.81	87 427,54
Buy	6.7			13.09.2023*	11:30 CEST	5.2	66 571.93

<sup>\*</sup> The report was prepared by Dom Maklerski BDM at the request of the WSE as part of the Exchange's Analytical Coverage Support Programme



#### Explanations of terminology:

EBIT - earnings before interest and tax

 ${\tt EBITDA-earnings\ before\ interest,\ taxes,\ depreciation,\ and\ amortization}$ 

Net debt – interest bearing debt minus cash and equivalents

WACC - weighted average cost of capital

CAGR - cumulative average annual growth

EPS - earnings per share

DPS - dividend per share

CEPS - net profit plus depreciation per share

EV - market capitalization plus interest bearing debt minus cash and equivalents

EV/S - market capitalization / sales

EV/EBITDA – EV / sales

P/EBIT – market capitalization / EBIT

MC/S — market capitalization / sales

P/E — market capitalization / net profit

P/BV — market capitalization / book value

P/CE - market capitalization / net profit plus depreciation

ROE - net profit / equity

ROA - net income / assets

Gross margin - gross profit on sales / sales

EBITDA margin – EBITDA / sales EBIT margin – EBIT / sales

Net margin – net profit / sales

#### The strengths and weaknesses of the valuation methods used in the report:

DCF – the most popular and the most effective of the valuation methods - it is based on the discounting of future cash flows generated by the company. The disadvantage is the high sensitivity to changes in the basic financial parameters forecast in the model (interest rates, exchange rates, profits, residual value).

DDM – the method is based on discounting future cash flows from dividends. The advantage of the valuation is the inclusion of future financial results and cash flows from dividends. The main disadvantages are the high sensitivity to changes in the basic financial parameters forecasted in the model (capital cost, profits, residual value) and the risk of changing the dividend payment policy.

Comparative – the method is based on current and forecasted market multipliers of companies from the companies—the includes based or further than DCF shows the current market situation. The main disadvantages are the difficulty in choosing the right companies for comparison, the risk of ineffective valuation of companies companed at a given moment, as well as high volatility (along with price fluctuations).

#### **Explanation of ratings:**

Buy – we believe that the security will reach the target price in the recommended period, which significantly exceeds the current market price (at least + 15%);

Accumulate – we believe that the security will reach the target price in the recommended period, which exceeds the current market price (in the range of +5 to + 14.99%);

Hold – we believe that a security in the recommended period will fluctuate around the target price, which is close to the current market price (in the range from -4.99% to + 4.99%);

Reduce - we believe that the security will reach the target price in the recommended period, which is lower than the market price (range of decline from 5% to 14.99%);

Sell – we believe that a security in the recommended period will reach the target price, which is significantly lower than the market price (suggested erosion of the value exceeds 15%). Target price – the theoretical price which, in our opinion, should reach a security in the recommended period; This price is the result of the company's value (eg based on DCF, comparative and other valuations), market conditions and the industry as well as other factors subjectively considered by the analyst.

Recommendations made by BDM are binding for 12 months from the issue date or until the target level is reached, unless they are updated during this period of time.

#### Distribution of BDM's recommendations in Q4'25\*:

. distribution of BDM's recommendations for the companies which BDM has supplied with investment banking services within the last 12 months

	Numbers	%	numbers	%
Buy	13	86%	0	0%
Accumulate	1	7%	0	0%
Hold	1	7%	0	0%
Reduce	0	0%	0	0%
Sell	0	0%	0	0%

<sup>\*</sup> detailed list of all analytical reports (recommendations) published by BDM during the last 12 months is included at https://www.bdm.pl/analizy-i-informacje/analizy/historia-rekomendacj



A Legal note:
This report (hereinafter also referred to as an analysis, a document) has been prepared in compliance with Regulation (EU) No. 596/2014 of the European Parliament and of the Council of 16 April 2014 (on market abuse), Commission Delegated Regulation (EU) 2016/958 and Commission Delegated Regulation (EU) 2017/565.

The report constitutes an investment research within the meaning of art. 36 §1 of Commission Delegated Regulation (EU) 2017/565.

The report has been prepared by Dom Maklerski BDM S.A. (hereinafter BDM S.A.) within the Exchange Analytical Coverage Support Programme (https://www.gpw.pl/gpwpa). BDM S.A. is a party to the

"Agreement on the provision of analytical report services" concluded with the Warsaw Stock Exchange Company ("GPW"), on the basis of which BDM provides services of analytical coverage of the Issuer for the term of the Agreement. Under the agreement BDM obtains remuneration from GPW. All materials prepared by BDM within the framework of co-operation are available at https://www.bdm.pl/program-wsparcia-pokrycia-analitycznego-gpw
The report has been prepared and made available for distribution by BDM.

GPW shall be a copyright holder to this report from the date of its publication. The report can be published and made available without limitation by GPW through any mass communication media as decided

This report does not constitute an investment, legal, accounting advice or any other, and BDM shall not be responsible for damages arising from or connected with the use of the data presented in the report or the use of any elements of the report by recipients. The report or any copy of it cannot be disseminated, directly or indirectly, in the United States, Canada, Australia or Japan, or transmitted to citizens or residents of a state where its distribution can restricted by law, which does not limit the possibility of publishing the report on internet websites of the Issuer, BDM or GPW. Persons who disseminate this document should be aware of the necessity to comply with such restrictions.

The document can be intended for professional or institutional customers of BDM as well as for other BDM qualified customers entitled to receive general recommendations based on agreements for

brokerage services. This report can also reach other entities through media distribution channels based on a decision of the manager of the analysis department. The fact that a recipient has obtained this report does not mean that he shall be treated as a BDM customer. The compilation cannot be published or copied without a prior written consent of BDM.

Persons who will receive this report and who are not professional customers or qualified investors should consult an independent financial advisor before making any investment decision based on this analysis in order to obtain any necessary and crucial explanations concerning the contents of this analysis.

To prepare this analytical report BDM has not considered individual needs or situations of customers. BDM is not obliged to guarantee that a financial instrument or financial instruments covered by this report are appropriate for a given investor.

Opinions of an analyst and any recommendations included in this report neither constitute an investment, legal, accounting or tax advice or a statement that any investment strategy is adequate or

appropriate because of individual circumstances concerning the customer, nor constitute personal recommendation.

The analysis is for information purposes only and does not constitute an advertisement or an offer or an invitation to subscribe or purchase financial instruments.

An investor should be aware that each investment decision in the capital market is subject to numerous risks that finally can result in a financial loss suffered by him. The return rate on individual investments can fluctuate depending on various factors beyond the control of the investor. Therefore, a customer who makes a single investment decision should not only check currency and correctness of individual assumptions made by the analyst in the report but also to have an independent assessment and own analysis (also based on scenarios other than the ones presented in the report) taking into consideration the level of acceptable risk. When deciding on activity on the capital market the Investor should take into consideration the fact that the investment portfolio structure (diversification of investment through possessing more than one financial instrument) can reduce risk exposure to an individual instrument bringing a negative rate of return in a given period. At the same time, however, it can lead to limitation of a positive rate of return the investor could achieve in the case of a single financial instrument in a given time period. The investor should be aware that the investment portfolio structure and any investment strategy for the stock market do not guarantee the achievement of a positive rate of return and do not protect him against final loss.

For the first time this report has been made available to the public on 18.12.2025 (07:50 CET). Date of preparing the report is the date of making it accessible. Before the recommendation was made

accessible, information included in it had been confidential.
The prices of the financial instruments listed in the document have been taken from the real-time pricing as provided by Bloomberg. Data concerning financial instrument prices used in the report could be

loaded to 24 hours before the moment of completing the report.

Detailed list of all analytical reports (recommendations) published by BDM during the last 12 months is included in a cyclical "Monthly Report".

In the opinion of BDM this report has been prepared observing principles of methodological correctness and objectivity on the basis of sources available to the public which BDM considers reliable. The sources of information used in recommendation are all data related to financial instruments concerned and available to an analyst, including current and periodic reports of the company, current and periodic reports of entities used for comparative valuation, business reports, press releases and other. However, BDM S.A., in no case, guarantees the accuracy and completeness of this report, in particular should sources on the basis of which the report was prepared prove to be inaccurate, incomplete or not fully consistent with the facts. The forecasts presented in the report are solely based on the analysis made by BDM without consultations with companies or other entities and are based on a number of assumptions which could prove to be wrong in the future. BDM does not guarantee that the presented forecasts will prove right.

Recommendations and by BDM are binding for 12 months from the issue date or until the target level is reached, unless they are updated during this period of time.

Any opinions, forecasts or estimates made in the report are merely an expression of analyst assessment as of the day of preparation of the report and at any moment they can be changed without notice.

BDM does not guarantee that the opinions or assumptions made by an analyst/analysts and included in this report are compatible with other analysis prepared by BDM. BDM updates issued recommendations depending on the market situation and analyst assessment, and the frequency obscut updates is not defined.

According to BDM this report has been made with due diligence and reliability. However, BDM shall not be held liable for any damages incurred as a result of decisions made on the basis of information

included in this report.

The report was not transferred to the issuer prior to its publication.

An analyst (analysts) preparing this document receives a fixed remuneration and the BDM Management Board has the right to grant them additional remuneration. Additional remuneration may indirectly depend on the results of other services offered by BDM, including investment banking services, but it shall not depend directly on financial results resulting from other services, including fin which have been or could have been reached by BDM.

BDM is not obliged to take any actions which could cause financial instruments that are the subject of the valuation contained in this document to be valued by the market in accordance with the valuation contained in this document.

The investor should assume that BDM employees or proxies or shareholders may hold long or short positions in the issuer's shares or other financial instruments related to the issuer's shares; this particularly concerns the situation of holding not more than 5% of the capital, and they may also carry out transactions on them as proxies.

Each of the above-mentioned persons could carry out transaction relating to the financial instruments concerned prior to this publication. At the same time, however, the instruments concerned are entered

in the restrictive list for employees of the Analysis Department immediately at the start of work on the report.

We have not identified significant conflicts of interest between BDM and persons associated with BDM and the financial instrument issuer. If a conflict of interest arises BDM shall manage it by applying the principles defined in the "Policy of management of conflicts of interest at the BDM S.A.". We point out that as for 18.12.2025:

- BDM states and assures that BDM is not involved financially in financial instruments of the Issuer.

  BDM is not a holder of net long or short positions exceeding the threshold of 0,5 % of the total issued share capital of the issuer,
- The person that participated in preparing recommendation is not a holder of net long or short positions exceeding the threshold of 0,5 % of the total issued share capital of the issuer,
- The issuer does not hold shares exceeding 5 % of the BDM issued share capital,
- BDM is not a market maker or liquidity provider in the financial instruments of the issuer,
  BDM has not been lead manager or co-lead manager over the previous 12 months of any publicly disclosed offer of financial instruments of the issuer;
- BDM is not a party to an agreement with the issuer relating to the provision of investment banking services pursuant to art. 69 §2 and 4 of the Act on Trading in Financial Instruments dated 25th July
- BDM is not a party to an agreement with the issuer relating to the provision of investment banking services pursuant to section A and B od Annex I to the Directive 2014/65/EU of the European Parliament and of the Council (hereinafter the Directive 2014/65/EU),
- BDM is not a party to an agreement with the issuer relating to the production of the recommendation,
  There is other significant financial interest that BDM or its related affiliates have in relation to the issuer of financial instruments\*,
- There are no significant connections between BDM or its related affiliates and the issuer of financial instruments
- The person affiliated with BDM who was involved in the preparation of recommendations did not receive or purchase the shares of the issuer, to whom the recommendation relates directly or indirectly, prior to public offering of such shares. The person affiliated with BDM who was involved in the preparation of recommendations declares that they respect internal regulations and are subject to organizational and technical solutions and
- information barriers established by BDM to eliminate any conflicts of interest concerning recommendations and to avoid them,
  The person affiliated with BDM who was involved in the preparation of recommendations was not rewarded in any form by the issuer, to whom the recommendation relates directly or indirectly, or
- was not directly connected with any possible transactions concerning services defined in art. 69 §2 and 4 of the Act on Trading in Financial Instruments dated 25th July 2005.

According to the best knowledge of the party recommending upon the publication of the report there are no other connections between BDM and the company described in this report that the party preparing this report would know of. However, the investor should be aware that the list disclosing conflicts of interest is long and that in the future there may occur situations leading to conflicts of interest which have not been identified or disclosed at the moment of publication of the report concerned. Especially, the investor should assume that BDM may submit an offer for services to a company or other

This document is a summary of a full version of the report prepared in Polish. In case of any disputes the Polish version shall prevail.

<sup>\*</sup>BDM is a party to the "ANALYTICAL REPORT PREPARATION SERVICES AGREEMENT" concluded with the WSE.